Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 6/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22003820 | 0.78 | ACLY (0.51) | ACLYTSHRLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL22004332 | 0.77 | ACLY (0.47) | ACLYHPGDTSHRHSD17B10ALDH1A1 | |
| SCHEMBL22004320 | 0.74 | MAPT (0.41) | ACLYLMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL22003794 | 0.71 | MAPT (0.46) | ACLYDHFRSLC2A1ALDH1A1SMN1; SMN2 | |
| SCHEMBL22004319 | 0.71 | ACLY (0.52) | ACLYHPGDALDH1A1MEN1MAPT | |
| SCHEMBL22004417 | 0.65 | ACLY (1.00) | ACLY | |
| SCHEMBL1885008 | 0.64 | KMT2A (0.42) | HPGDTSHRHSD17B10LMNADHFR | |
| SCHEMBL24345321 | 0.61 | ALDH1A1 (0.47) | DHFRSLC2A1ALDH1A1 | |
| SCHEMBL22939250 | 0.61 | DHFR (0.38) | DHFRSLC2A1ALDH1A1MAPT | |
| SCHEMBL23847834 | 0.61 | PTGS1 (0.46) | HPGDTSHRHSD17B10LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020102616-A1 | ACLY INHIBITORS AND USES THEREOF | Nimbus Artemis, Inc. (US) | 2020-05-22 | — | — | WO | disclosed |
| US-20200157076-A1 | ACLY INHIBITORS AND USES THEREOF | NIMBUS DISCOVERY, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157076-A1 | ACLY INHIBITORS AND USES THEREOF | ACLY, ATP5ME, ATP5MG | ACLY 1/4885HPGD 1212/4885TSHR 4803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.